RE:Tilray Brands AGM - Nov 23, 2023 Following question of M&A from Matt Bottomley - Cannacord
has opened up some remarks about Tilrays next moves. CRON has some of those openings filled?
I'm not sure how CRON is developed in Australia?
Q1 2024 Earnings Call
Oct 04, 2023, 8:30 a.m. ET
NOTE: Tilray keeping their cards close to their chests but CRON does have Edibles that Blair mentions below, and European operations.
Matt Bottomley -- Canaccord Genuity -- Analyst
Hey, good morning, everyone. I just wanted to first touch base on -- on kind of that first strategic priority and we were just sort of talking about it now with respect to some of the organic growth. But on the M&A front, what is the current landscape if we're looking at, you know, the cannabis sector in general and federally legal environments with respect to what we're seeing in Canada and international markets? Is this something that you think probably has the least amount of, you know, opportunistic assets out there just given some of the headwinds we've seen in federal markets? And should we expect maybe more beverage alcohol focus when it comes to M&A allocation? I'm just curious if you have an indication one way or the other.
Irwin Simon -- Chairman and Chief Executive Officer
So, I'm going to bring two other people in to talk about that, Blair MacNeil here who runs Canada...
Blair MacNeil -- President, Canadian Business
Yeah. So, you know, to your question, Matt, on the -- on the opportunity on the M&A side, from an asset standpoint, I think if you look at our portfolio, we're very well rounded. I'd say, you know, maybe we've got a small gap on the edibles side, but when you look at the rest of our portfolio, we are very well represented. So, there's not a lot of assets out there that we would look to acquire over the next period of time.
We do have, as Irwin alluded to, all of our facilities are starting to really get up there and utilization, and we have availability of some capacity to be able to bring edibles into that. So, we'll -- we'll look to do that over this next period of time. So, you know, at least from a Canadian perspective, I'm happy with the growth we're seeing in the market; I'm happy with where the industry is. You know, not without its challenges, as Irwin said, but from an M&A standpoint, we don't see a lot of opportunity there.
Irwin Simon -- Chairman and Chief Executive Officer
And before I pass it to Denise for Europe, we're really excited about the beverage category...
Denise Faltischek -- President, International Business and Chief Strategy Officer
Thanks, Irwin. Yeah, so internationally, if you look at Europe first, really the only cannabis market today is a medical cannabis market, and Germany still remains the largest market within -- within Europe. However, we do see some countries that are coming online and developing very quickly. The regulations are still -- as we all know, are still really shaping out.
We are looking to see medical cannabis in Germany become -- be scheduled as a narcotic and become a regular medicine that can be prescribed. And so, if we look at our business, we really see like our business is very nascent today and is still developing. And so, we are evaluating where do we have gaps and capabilities and where can, potentially, M&A fill in those gaps. And so, we are very much looking to see what is out there, what -- what can we do to make our business, have full capabilities, whether it's technology, whether it's online platforms, etc.
And we are looking at the same thing in Australia, New Zealand, whether it's looking at clinics, etc., and then also talking about potentially looking at how beverage alcohol might play a role in Europe as well. So, we are very much focused in seeing what might be available to round out our capabilities and -- and make a more fulsome business.